VistaGen Therapeutics (VTGN) Stock News
$VTGN · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on VistaGen Therapeutics (VTGN) in the past 30 days. VistaGen Therapeutics’ next earnings report is scheduled for Thursday, Nov 12.
The wire on $VTGN
newest first · updated · direct subject stories onlyVistagen Reports Positive Findings Supporting fasedienol in Very Severe social anxiety disorder
Exploratory subpopulation analyses from two trials show statistically significant benefit in very severe SAD patients, though the Phase 3 study missed its primary endpoint in the overall population.
bullish 70 · impact 40The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
BORSAPLUSNews on Price · Earnings read · Flow and ownership · Options context
Create a free account · no card VistaGen Therapeutics (VTGN) stock: common questions
What is the latest VistaGen Therapeutics stock news?
The highest-impact VTGN story BORSA published in the past 30 days:
· Vistagen Reports Positive Findings Supporting fasedienol in Very Severe social anxiety disorder